Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nanexa AB has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to 2 distinct examiners. Notably, the prosecution is occurring across 2 distinct art units, meaning each pending matter is being evaluated in a different administrative and technical environment. This complete separation across 2 distinct art units and 2 distinct examiners suggests that the company's current filings cover distinct technical innovations within the broader biotechnology field, requiring independent prosecution strategies for each case.
BERRIOS, JENNIFER A is the busiest examiner, currently managing 1 pending office action. This busiest examiner pending count represents one of the 2 total pending office actions. With 2 distinct examiners and 2 distinct art units, there is no overlap in the personnel or the specific art units handling the company's current workload. Practitioners must develop separate strategies for each of the 2 pending office actions, as the lack of examiner or art unit overlap limits the ability to use one case as a direct precedent for the other, necessitating a more resource-intensive approach to the active docket.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERRIOS, JENNIFER A | 1 | 37.0% | +49.8% |
| PROCTOR, CACHET I | 1 | 77.1% | +5.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18567466 | NEW PROCESS | PROCTOR, CACHET I | 49d overdue |
| 18717160 | NEW INJECTABLE COMBINATION FORMULATION | BERRIOS, JENNIFER A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717160 | NEW INJECTABLE COMBINATION FORMULATION | BERRIOS, JENNIFER A | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1712 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717160 | NEW INJECTABLE COMBINATION FORMULATION | BERRIOS, JENNIFER A | 1613 | §103§112 | Non-Final OA | — | Pending | Jun 06, 2024 |
| 18567466 | NEW PROCESS | PROCTOR, CACHET I | 1712 | §102§103 | Non-Final OA | 49d overdue | Pending | Dec 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial